In primary patient samples NADPH levels were significantly reduced relative to CD34+ controls for IDH1-mutant, but not IDH2-mutant AML (Fig. 4e), consistent with reports from studies with IDH1-mutant solid tumours41,49,52. Here, CD34 is linked to acute myeloid leukemia.